知镜 Cognispect · 医学文献与研究工作台

Molecular profiling of ovarian cancer is feasible and provides valuable therapeutic and research information to women in Aotearoa New Zealand.

Simcock B, Wilson M, Vaughan M, Sykes P, Bell R, Nevins N, Mapagu C, Bouantoun N, Provan P, Lee E, Balleine R, DeFazio A.
The New Zealand medical journal · 2026-10-23 · PMID 42912973

文献摘要

Aim Molecular profiling of ovarian cancer is feasible and provides valuable therapeutic and research information to women in Aotearoa New Zealand. Method Sixteen women consecutively diagnosed with apparent advanced ovarian, fallopian tube or primary peritoneal cancer underwent molecular profiling as part of INOVATe (Individualised Ovarian Cancer Treatment through Integration of Genomic Pathology into Multidisciplinary Care), an ovarian cancer precision medicine programme conducted in New South Wales, Australia. Results All eligible women who were approached agreed to participate in the study. Molecular profiling was successfully undertaken on tumour tissue samples stored after primary surgery and in two of three core biopsy samples. Six of 9 women (67%) with high-grade serous ovarian carcinoma had tumour samples classified as having homologous recombination deoxyribonucleic acid (DNA) repair deficiency, an alteration that predicts response to poly (ADP-ribose) polymerase inhibitors. Overall, 7/15 (47%) with a sample available for testing had a tier 1 molecular alteration, indicating the potential for a Food and Drug Administration-approved therapy. Additional potentially targetable alterations included CCNE1 gene amplification in two patients with high-grade serous ovarian carcinoma, and PIK3CA mutations in two patients with clear cell ovarian cancer. Conclusion Molecular profiling of ovarian cancer is feasible and provides valuable information that can guide available therapeutic options and selection into clinical trials.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。